| Patents for A61K 38 - Medicinal preparations containing peptides (316,240) |
|---|
| 08/11/2005 | US20050176661 Antiviral oligonucleotides |
| 08/11/2005 | US20050176660 Use of specific antisense-based constructs and peptide-specific polyclonal and monoclonal antibodies in leukemia, acute or chronic tissue damages, HIV-related damage of brain or other tissues, skeletal muscle disorders, transplantation rejection; Parkinson's disease; amyotrophic lateral sclerosis |
| 08/11/2005 | US20050176659 Polypeptide contributing to regulating the metabolism of triglycerides; obesity as well as related disorders such as eating disorder, cachexia, diabetes mellitus, hypertension, coronary heart disease, hypercholesterolemia, dyslipidemia, osteoarthritis, gallstone, cancers of the reproductive organs |
| 08/11/2005 | US20050176651 Peptide boronic acids useful in making salts thereof |
| 08/11/2005 | US20050176649 complexing apoptosis protein with a labeled compound to form a complex having the measurable feature; contacting the labeled compound/IAP complex with the test agent; measuring displacement of the complex; drug screening; anticarcinogenic agent |
| 08/11/2005 | US20050176648 oligopeptide including enantiomers, stereoisomers and tautomers, used as hepatitis c protease enzyme inhibitors for prophylaxis or prevention of viral diseases |
| 08/11/2005 | US20050176646 Covalently bonding a narcotic to a single amino acid or an oligopeptide of 15 or fewer amino acids such that the narcotic does not release into a patient's bloodstream at levels that give rise to a euphoric or overdose level |
| 08/11/2005 | US20050176645 Abuse-resistant hydrocodone compounds |
| 08/11/2005 | US20050176644 Covalently bonding at 6' position and 14' position of oxycodone a single amino acid or oligopeptide of 12 or fewer amino acids; when delivered at proper dosage composition provides therapeutic activity similar to that of parent active agent; when delivered at higher dose potential for overdose is reduced |
| 08/11/2005 | US20050176643 Anti-obesity agents |
| 08/11/2005 | US20050176642 Enhancing anti-HIV efficiency through multivalent inhibitors targeting oligomeric GP120 |
| 08/11/2005 | US20050176641 Long lasting natriuretic peptide derivatives |
| 08/11/2005 | US20050176640 poxvirus protein A41L binds to leukocyte common-antigen-related protein; monoclonal antibody; therapeutic agents for an immune and/or inflammatory response; poxvirus |
| 08/11/2005 | US20050176639 Use of osteopontin for the treatment and/or prevention of neurologic diseases |
| 08/11/2005 | US20050176638 Product derived from milk substantially free of beta casein from non-human mammals and relative use |
| 08/11/2005 | US20050176637 Administering a peptide having a sequence of QPLALEGSLQK in combination with another polypeptide to treat insulin dependent diabetes mellitus (IDDM or Type 1 diabetes) |
| 08/11/2005 | US20050176636 Peptides of 38 amino acids, including therein a sequence of L-K-E-K-K, have physiological activity that can be wound healing activity, immunostimulant activity, or stimulating pituitary/hypothalamus activity in a mammal |
| 08/11/2005 | US20050176635 Remedy for bone mtabolic diseases |
| 08/11/2005 | US20050176634 substitution or the elimination ofcysteine residue (Cys) in the C-terminal portion of the wild type protein polypeptide sequence; prevents multimerisation of monomeric form but does not affect dimerisation; storage stability; treatment of ischemia, scleroderma, skin ulcer, aging, burn, wound; cosmetic |
| 08/11/2005 | US20050176633 low-molecular weight compounds, peptides and proteins, particularly antibodies or antibody fragments; drug screening; increased G-protein mediated signal transduction |
| 08/11/2005 | US20050176632 Angiogenesis inhibitors |
| 08/11/2005 | US20050176631 Method for reducing morbidity and mortality in critically ill patients |
| 08/11/2005 | US20050176630 Modification of feeding behavior |
| 08/11/2005 | US20050176629 Telomerase expression repressor proteins and methods of using the same |
| 08/11/2005 | US20050176628 Deuterated cyclosporin analogs and their use as immunomodulating agents |
| 08/11/2005 | US20050176627 increasing the hematocrit of an individual while maintaining the tissue protective activities of endogenous erythropoietin through the administration of a pharmaceutical compound containing chemically modified long acting erythropoietin. Also disclosed are the new erythropoietins |
| 08/11/2005 | US20050176626 modulating production of neurons and/or oligodendrocytes from neural progenitor cells of human white matter and to a method of treating a subject for a condition modulated by underproduction of oligodendrocytes from human white matter, sterol inhibitors |
| 08/11/2005 | US20050176625 Synthetic lipid mixtures for the preparation of a reconstituted surfactant |
| 08/11/2005 | US20050176624 Organometallic complexes as singlet oxygen sensitizers |
| 08/11/2005 | US20050176623 Non-invasive treatment of disease using amphipathic compounds |
| 08/11/2005 | US20050176622 secondary binding site of dipeptidyl peptidase IV, its relationship amongst substrates and to the modulation of substrate specificity of dipeptidyl peptidase IV (DP IV, synonym: DPP IV, CD26, EC 3.4.14.5). The application relates further to compounds that bind to the secondary binding site of DP IV |
| 08/11/2005 | US20050176621 Crystalline compositions for controlling blood glucose |
| 08/11/2005 | US20050176620 Crosslinked compounds and methods of making and using thereof |
| 08/11/2005 | US20050176142 Mammalian megakaryocyte progenitor cell |
| 08/11/2005 | US20050176123 Protease inhibitor |
| 08/11/2005 | US20050176107 Antibody constant region fused to an OB protein; ditetics; useful for decreasing the amount of insulin necessary for the treatment of diabetes |
| 08/11/2005 | US20050176105 Used in cell culture media, and as inhibitors of protease-mediated degradation of plasma proteins in protein purification; fewer side effects than traditional anticoagulants |
| 08/11/2005 | US20050176103 Produced by recombinant techniques and polynucleotides encoding the polypeptides; used to stimulate angiogenesis for wound healing and for vascular tissue repair |
| 08/11/2005 | US20050176100 Zinc metalloprotease angiotensin-converting enzyme (ZACE-1) for use in identifying blood pressure and fertility modulators |
| 08/11/2005 | US20050176098 Human ion channels |
| 08/11/2005 | US20050176094 Polypeptide having immunomodulatory activity, antiviral activity, and antitumor activity; polynucleotides, expression vectors , probes and antibodies; predicting responsiveness to treatment with interferon- alpha and other interferons which act at the Type 1 interferon receptor |
| 08/11/2005 | US20050176083 Blood protein fusion comprising serine-protease (SP) domain for use in treatment of thrombosis a nd blood coagulation disorders |
| 08/11/2005 | US20050176061 Using signal sequence polypeptide to diagnose/prognose diabetic disorders; antidiabetic agents |
| 08/11/2005 | US20050176060 Crystal structure |
| 08/11/2005 | US20050176044 Polynucleotides and polypeptides encoding receptors |
| 08/11/2005 | US20050176038 Transcribed non-naturally occurring RNA sequences which form hairpin structures for use in treatment of cell proliferative disorders; gene therapy; antisense agents |
| 08/11/2005 | US20050176025 RNA interference mediated inhibition of B-cell CLL/Lymphoma-2 (BCL-2) gene expression using short interfering nucleic acid (siNA) |
| 08/11/2005 | US20050176024 chemically synthesized double stranded siNA that directs cleavage of EGFR such as HER1, HER2, HER3 or HER4; diagnosis or treatment of cancer for example |
| 08/11/2005 | US20050176022 Vertebrate telomerase genes and proteins and uses thereof |
| 08/11/2005 | US20050176021 Vectors for propagating and expressing RGL3 nucleic acids, host cells comprising the nucleic acids; proteins; cancer |
| 08/11/2005 | US20050176020 I-CAM related protein |
| 08/11/2005 | US20050176018 Increased nuclease resistance; gene expression inhibition |
| 08/11/2005 | US20050176010 Regulation of human transient receptor potential channel |
| 08/11/2005 | US20050176004 Rheumatoid arthritis disease sensitive gene, its protein, method and kit of judging the onset of rheumatoid arthritis using the same, and method and drugs for treating rheumatoid arthritis |
| 08/11/2005 | US20050175994 Methods and materials relating to prothrombinase-like polypeptides and polynucleotides |
| 08/11/2005 | US20050175725 Body fat percentage-lowering agent or body fat percentage increase inhibitor |
| 08/11/2005 | US20050175724 Composition for modulating at least one physiological reaction or inducing an immune response in human or animal after oral administration; for intestinal delivery of a physiologically active agent, a neutralizing agent, an inhibitor of digestive enzymes, an uptake increasing agent; synergistic |
| 08/11/2005 | US20050175703 Polymer compositions and methods for their use |
| 08/11/2005 | US20050175666 Bioabsorbable stents; vascular disorders, occlusion treatment such as restenosis or vulnerable plaque; atherosclerosis, diabetes; anticoagulants |
| 08/11/2005 | US20050175665 In combination with antiscarring, antifibrotic, and antiinflammatory agents for preventing surgical adhesions, and cartilage loss; hypertrophic scars, keloids, arthritis, vascular disease; injection or topical administration |
| 08/11/2005 | US20050175664 Breast, pectoral, chin, facial, lip, and nasal implants; inhibits angiogenesis and fibroblast migration; enzyme inhibitors |
| 08/11/2005 | US20050175663 Medical implants and anti-scarring agents |
| 08/11/2005 | US20050175662 Intravascular devices and fibrosis-inducing agents |
| 08/11/2005 | US20050175661 Intravascular devices and fibrosis-inducing agents |
| 08/11/2005 | US20050175657 An injectable mixture of a bulking agent and a fibrosing agent chosen from silkworm silk, spider silk, talc, chitosan, polylysine, fibronectin, bleomycin or connective tissue growth factors; increased fibrosis between implant and host tissue |
| 08/11/2005 | US20050175637 Methods for enhancing wound healing |
| 08/11/2005 | US20050175636 Containing stabilized neurotoxin as analgesic and skin penetration enhancing agent; inflammation and/or pain reduction |
| 08/11/2005 | US20050175633 Polynucleic acids isolated from a porcine reproductive and respiratory syndrome virus (PRRSV), proteins encoded by the polynucleic acids, vaccines based on the proteins and/or polynucleic acids, a method of protecting a pig from a PRRSV and a method of detecting a PRRSV |
| 08/11/2005 | US20050175631 Hiv vaccine and method of use |
| 08/11/2005 | US20050175627 HIV pharmaccines |
| 08/11/2005 | US20050175624 Utilizing vascular epithelial growth factor (VEGFR1) polypeptides, fragments and/or encoding oligonucleotides |
| 08/11/2005 | US20050175620 Multivalent platform molecules comprising high molecular weight polyethylene oxide |
| 08/11/2005 | US20050175613 Compositions and methods for treating hyperimmune response in the eye |
| 08/11/2005 | US20050175612 Growth differentiation factor-8 |
| 08/11/2005 | US20050175610 Modified chimeric polypeptides with improved pharmacokinetic properties and methods of making and using thereof |
| 08/11/2005 | US20050175604 Administering a plurality of two autoimmune inhibitors selected from the group consisting of an antibody to alpha interferon, an antibody to gamma interferon, and an antibody to tumor necrosis factor alpha |
| 08/11/2005 | US20050175603 Reduced-viscosity concentrated protein formulations |
| 08/11/2005 | US20050175602 Mixing protein with a saccharide compound in a liquid suspension and then drying to produce a solid that contains the protein and the saccharide |
| 08/11/2005 | US20050175601 Use of LIMK-1, its analogues and ligands for the production of a medicament against a thrombus formation or blood clotting disease |
| 08/11/2005 | US20050175600 Wound healing compositions and methods using tropoelastin and lysyl oxidase |
| 08/11/2005 | US20050175593 For prevention of plant diseases; cell-free extracts |
| 08/11/2005 | US20050175586 Method of treating anemia caused by ribavirin treatment of hepatitis C using erythropoietin alpha |
| 08/11/2005 | US20050175585 Combination therapies using vitamin B12 and interferon for treatment of viral proliferative and inflammatory disesases |
| 08/11/2005 | US20050175584 Functionalized colloidal metal compositions and methods |
| 08/11/2005 | US20050175583 Making vector compositions that mimic the functionality of components of the immune system especially antigen-presenting cell (APC) element of the immune synapse; vaccination |
| 08/11/2005 | US20050175582 Non-antigenic toxin-conjugate and fusion protein of internalizing receptor system |
| 08/11/2005 | US20050175581 Engineered proteases which hydrolyze specific peptide bonds within target substrate |
| 08/11/2005 | US20050175580 Compositions and methods for enhancing cytokine activity and treating hypotension associated with the administration of cytokines |
| 08/11/2005 | US20050175579 linear, cross-linked or high molecular weight acrylic acid-based polymers: polyacrylic acid cross-linked with allyl sucrose, allylpentaerythritol, acrylic or methacrylic acid or both modified with c10-c30 acrylate, crosslinked by allyl ethers as modulator of the enzyme responsible for inflammation |
| 08/11/2005 | US20050175556 Tyrosine, dihydroxy phenylalanine, L-DOPA, Mucuna prurience extract, catechol or derivatives as tyrosinase substrate; copper ATP, Glutathione, Cystine, Cysteine, N-Acetyl-Cystine, N-Acetyl-Cysteine or copper complex of these amino acids as tyrosinase activatior; a delivery system or carrier |
| 08/11/2005 | US20050175553 new members of the TGF- beta protein family with mitogenic and/or differentiation-inductive potential; pharmaceutical composition further comprising a growth/differentiation factor selected from the group consisting of MP-121, epidermal growth factor and platelet derived growth factor |
| 08/11/2005 | CA2851972A1 Methods for reducing oxidative damage |
| 08/11/2005 | CA2595520A1 Hsp therapy in conjunction with a low antigenicity diet |
| 08/11/2005 | CA2556849A1 Inhibition of bright function as a treatment for excessive immunoglobulin production |
| 08/11/2005 | CA2554994A1 Haemostatic sprays and compositions |
| 08/11/2005 | CA2554883A1 Production and purification of recombinant arylsulfatase a |
| 08/11/2005 | CA2554755A1 Functionalized colloidal metal compositions and methods |
| 08/11/2005 | CA2554599A1 Novel brain natriuretic peptide variants and methods of use thereof |
| 08/11/2005 | CA2554475A1 Pituitary adenylate cyclase activating peptide (pacap) receptor (vpac2) agonists and their pharmacological methods of use |
| 08/11/2005 | CA2554458A1 The combined use of glp-1 agonists and gastrin for regulating blood glucose levels |